Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Trajan Group HoldingsTRJNF 38 PS Ratio is 0.55 as of Jul. 14, 2026, which is 53% below its 10-year median of 1.16. GuruFocus rates TRJNF with a GF Score™ of 38/100 and a GF Value™ of $1.53. The stock has 2 warning signs investors should review. Among 806 Medical Devices & Instruments companies, Trajan Group Holdings ranks better than 97.02% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Trajan Group Holdings's share price is $0.40.
Trajan Group Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.73. Hence, Trajan Group Holdings's PS Ratio for today is 0.55.
The historical rank and industry rank for Trajan Group Holdings's PS Ratio or its related term are showing as below:
TRJNF'
s PS Ratio Range Over the Past 10 Years
Min: 0.18 Med: 1.16 Max: 2.97
Current: 0.26
During the past 5 years, Trajan Group Holdings's highest PS Ratio was 2.97. The lowest was 0.18. And the median was 1.16.
TRJNF's PS Ratio is ranked better than 97.02% of 806
companies
in the Medical Devices & Instruments industry
Industry Median: 2.88
vs TRJNF: 0.26
During the past 5 years, Trajan Group Holdings's highest 3-Year average Revenue per Share Growth Rate was 11.50% per year. The lowest was -19.20% per year. And the median was -3.85% per year.
Back to Basics: PS Ratio
Trajan Group Holdings (OTCPK:TRJNF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Trajan Group Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trajan Group Holdings PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Trajan Group Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where Trajan Group Holdings's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Trajan Group Holdings's Share Price of today is $0.40.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Trajan Group Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.73.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Trajan Group Holdings (TRJNF) has a PS Ratio of 0.55 as of Jul. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Trajan Group Holdings and its competitors. This is 53% below median its historical median of 1.16. Over the past decade, Trajan Group Holdings' PS Ratio has ranged from 0.18 to 2.97. According to the industry distribution chart, Trajan Group Holdings ranks #24 out of 806 companies in the Medical Devices & Instruments industry, placing it in the top 3%.
Is Trajan Group Holdings' PS Ratio too high?
Trajan Group Holdings' current PS Ratio of 0.55 is 53% below median its 10-year median of 1.16. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 2.97. The Medical Devices & Instruments industry median PS Ratio is 2.88. Trajan Group Holdings' value of 0.55 is 80.9% below this industry median. Based on the distribution chart, Trajan Group Holdings ranks #24 out of 806 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Trajan Group Holdings has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Trajan Group Holdings' PS Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Trajan Group Holdings ranks #24 out of 806 companies for PS Ratio. This places Trajan Group Holdings in the top 3% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.88. Trajan Group Holdings' value of 0.55 is 80.9% below this benchmark. Historically, Trajan Group Holdings' own PS Ratio has ranged from 0.18 to 2.97 over the past decade. While the company's 10-year median is 1.16 vs. the industry median of 2.88, Trajan Group Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.88, based on 806 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Trajan Group Holdings's current PS Ratio of 0.55 is 80.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Trajan Group Holdings and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trajan Group Holdings's current PS Ratio is 0.55, which is 53% below median its own 10-year median of 1.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trajan Group Holdings stock overvalued right now?
Trajan Group Holdings (TRJNF) has a current PS Ratio of 0.55. The stock's GF Value™ is $1.53, compared to a current price of $0.40 — trading 73.9% below its estimated fair value. The current PS Ratio is 0.55, which is 53% below median its 10-year median of 1.16 and 80.9% below the Medical Devices & Instruments industry median of 2.88. Trajan Group Holdings' overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Trajan Group Holdings (TRJNF), the current PS Ratio is 0.55 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trajan Group Holdings (TRJNF) Overvalued in 2026?
Based on GuruFocus' analysis, Trajan Group Holdings stock appears to be undervalued.
The current stock price of $0.40 is trading 73.9% below its estimated GF Value™ of $1.53.
Key valuation signals for TRJNF:
PS Ratio: 0.55 (53% below median its 10-year median of 1.16)
GF Value™: $1.53 vs. price of $0.40 (73.9% below fair value)
Industry Position: 80.9% below the Medical Devices & Instruments median (#24 of 806)
No single metric tells the full story. See the TRJNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trajan Group Holdings Ltd is a developer and manufacturer of analytical and life sciences products and devices, seeking to enrich human well-being through scientific measurement. Its current portfolio of products comprises products, devices and solutions that are used in the analysis of biological, food, and environmental samples. The Group now reports in three operating segments: Components and Consumables, Capital Equipment and Disruptive Technologies. Key revenue is generated from Components and consumables, which include parts, supplies, components, and consumable products worldwide. The Group operates in Asia (Malaysia, Japan and Australia and New Zealand (ANZ)), USA and Europe, Middle East, Africa, and India (EMEA).
38GF Score
Get the complete analysis for TRJNF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRJNF has been successfully added to your 
